Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Drops By 47.3%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 57,108 shares, a decrease of 47.3% from the June 30th total of 108,461 shares. Based on an average daily trading volume, of 69,290 shares, the short-interest ratio is currently 0.8 days. Approximately 1.0% of the company’s shares are short sold.

iShares Genomics Immunology and Healthcare ETF Price Performance

Shares of IDNA stock traded up $0.64 during trading on Thursday, hitting $32.79. 17,579 shares of the stock traded hands, compared to its average volume of 43,204. The firm has a market capitalization of $193.46 million, a P/E ratio of 14.76 and a beta of 0.92. The firm’s fifty day moving average price is $31.58 and its 200-day moving average price is $30.18. iShares Genomics Immunology and Healthcare ETF has a 52-week low of $20.93 and a 52-week high of $34.97.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management purchased a new position in shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,481 shares of the company’s stock, valued at approximately $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.